Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, and also sells active pharmaceutical ingredient products. Its finished products are distributed through group purchasing organizations, drug wholesalers, and drug retailers, with many used in hospital or urgent care settings.
Company news commonly covers quarterly financial results, product sales trends for therapies such as BAQSIMI®, Primatene MIST®, glucagon and epinephrine products, FDA approvals and launches, and spending on insulin, inhalation, and proprietary pipeline programs. Updates also include licensing activity, including AMP-110, a fully synthetic corticotropin compound for inflammatory and autoimmune conditions, as well as healthcare conference presentations and corporate communications.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q1 2026 net revenue of $171.2M, GAAP net income of $6.4M ($0.14 diluted) and adjusted non-GAAP net income of $19.5M ($0.42 diluted). Gross margin fell to 41.1%. The company launched Ipratropium Bromide HFA, in‑licensed a synthetic corticotropin, and holds multiple ANDA/biosimilar filings and pipeline programs. A conference call is scheduled May 7, 2026 at 2:00 p.m. PT.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 2026 Bank of America Health Care Conference on May 13, 2026 at 3:00 pm PT. Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will discuss corporate strategy. The webcast is available at Amphastar's investor website and will remain online for 30 days.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will release first quarter 2026 results for the period ended March 31, 2026, after market close on May 7, 2026, and will hold a conference call the same day at 2:00 p.m. PT. The live call and webcast are available on the company's Investors page; a replay will be posted within 24 hours.
Dial-in numbers are toll-free 877-407-0989 or international 201-389-0921. The company develops and sells injectable, inhalation, intranasal, and API products distributed through GPOs, wholesalers, and retailers.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 25th Annual Needham Healthcare Conference on April 14, 2026 at 11:45 am ET. Executives Bill Peters (CFO), Tony Marrs (EVP Regulatory & Clinical) and Dan Dischner (SVP Corporate Communication) will speak.
The presentation will be streamed via webcast and will be available for 30 days after the presentation. Investors can access the webcast through Amphastar's investor website.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q4 2025 net revenues of $183.1M and fiscal 2025 net revenues of $719.9M. GAAP net income was $24.4M in Q4 and $98.1M for the year; GAAP diluted EPS was $0.51 and $2.03, respectively. Adjusted non-GAAP net income was $34.2M for Q4 and $156.6M for the year. BAQSIMI drove double-digit growth, iron sucrose and teriparatide received FDA approvals, R&D and G&A rose due to clinical programs, ERP and a $23.1M legal settlement. Cash flow from operations was $156.1M.
Amphastar (NASDAQ:AMPH) announced FDA approval of its Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation, found bioequivalent and therapeutically equivalent to Atrovent HFA. The FDA confirmed 180 days of generic exclusivity as the first Paragraph IV ANDA filer.
The company plans a commercial launch early in Q2 2026. IQVIA U.S. sales for Atrovent HFA were about $112 million for the 12 months ended December 31, 2025. Amphastar also disclosed multiple ANDA and biosimilar filings and development programs targeting markets worth billions.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will release fourth-quarter 2025 results after market close on Thursday, February 26, 2026 and will host a conference call the same day at 2:00 p.m. Pacific Time.
Investors can access the live call by dialing the provided toll-free or international numbers or via the company's Investors page at www.amphastar.com; a webcast replay will be posted within 24 hours.
Amphastar (NASDAQ:AMPH) entered an exclusive U.S. and Canada license with Nanjing Hanxin for AMP-110, a fully synthetic human ACTH analog targeting inflammatory and autoimmune conditions.
Key deal terms include a $2 million upfront payment, up to $14 million in development milestones, up to $75 million in sales milestones, and royalty payments to Hanxin not to exceed $7.5 million per year with a $60 million cumulative cap. Hanxin retains non-exclusive rights outside the U.S. and Canada. AMP-110 is in early-phase human studies with an early promising safety profile. The U.S. ACTH market exceeded $684 million in 2024.
Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 PM PT. Jack Zhang, CEO and President, and Bill Peters, CFO, will deliver the presentation. A live webcast will be available at http://ir.amphastar.com and will remain accessible for 30 days after the presentation.
Amphastar focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and sells insulin active pharmaceutical ingredient products. Most finished products are used in hospital or urgent care settings and are distributed via group purchasing organizations and drug wholesalers.
Amphastar (NASDAQ: AMPH) announced FDA approval of its ANDA for teriparatide injection, USP 560 mcg/2.24 mL (250 mcg/mL) single‑patient‑use prefilled pen, judged bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO.
Company plans a commercial launch by end of 2025, notes U.S. teriparatide sales of ~$585 million for the 12 months ended September 30, 2025 (IQVIA), and says the product is manufactured entirely in‑house at its U.S. facility.